(Reuters) – A Pfizer Inc lung cancer drug appears to be a highly effective treatment for children with a rare but aggressive type of lymphoma and other cancers, according to data from an early stage study.
The drug, crizotinib, was able to stall tumor growth and in some cases eradicate all signs of particularly aggressive cancers with minimal side effects, researchers said.
The study highlights a new understanding of how some cancers operate, one that is based on the patient’s genetic profile rather than the organ in which the tumor originates.  The hope is that by identifying more instances of a genetic connection, doctors will be better able to target a drug for treatment. <Read More>
Â
Visit msnbc.com for breaking news, world news, and news about the economy
Drug combination boosts effectiveness of crizotinib…
Targeted drugs are new approach to kid cancer treatment…
The risks versus benefits of kid clinical trials…




